


Cite this: *RSC Adv.*, 2021, 11, 1773

Development of bactericidal spinel ferrite nanoparticles with effective biocompatibility for potential wound healing applications

Atiya Rabbani,^a Reihaneh Haghniaz,^b Taous Khan,^c Romana Khan,^d Ayesha Khalid,^a Syeda Sohaila Naz,^e Mazhar Ul-Islam,^f Fereshteh Vajhadin^g and Fazli Wahid ^{*ah}

The current study was devised to explore the antibacterial activity and underlying mechanism of spinel ferrite nanoparticles (NPs) along with their biocompatibility and wound healing potentials. In this regard, nickel ferrite and zinc/nickel ferrite NPs were synthesized *via* a modified co-precipitation method and were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDX). The biocompatibility of the synthesized NPs with human dermal fibroblast (HDF) and red blood cells (RBCs) was assessed. The biocompatible concentrations of the NPs were used to investigate the antimicrobial activity against various pathogenic Gram-negative and Gram-positive bacteria. The mode of bactericidal action was also explored. *In vitro* scratch assay was performed to evaluate the wound healing potential of NPs. The SEM-EDX analysis showed that the average particles size of nickel ferrite and zinc/nickel ferrite were 49 and 46 nm, respectively, with appropriate elemental composition and homogenous distribution. The XRD pattern showed all the characteristic diffraction peaks of spinel ferrite NPs, which confirmed the synthesis of the pure phase cubic spinel structure. The biocompatible concentration of nickel ferrite and zinc/nickel ferrite NPs was found to be 250 and 125 $\mu\text{g ml}^{-1}$, respectively. Both the NPs showed inhibition against all the selected strains in the concentration range of 50 to 1000 $\mu\text{g ml}^{-1}$. Studies on the underlying antimicrobial mechanism revealed damage to the cell membrane, protein leakage, and intracellular reactive oxygen species production. The *in vitro* scratch assay confirmed the migration and proliferation of fibroblast with artificial wound shrinkage. This study shows that nickel ferrite and zinc/nickel ferrite NPs could be a strong candidate for antibacterial and wound healing nano-drugs.

Received 2nd October 2020
Accepted 20th December 2020

DOI: 10.1039/d0ra08417d

rsc.li/rsc-advances

1. Introduction

The rise of antibiotic resistance is becoming a global public health crisis.¹ Although, the misuse of antibiotics for the treatment of human diseases is the major cause of the problem,

the overuse of antimicrobial agents in veterinary medicines, agriculture and industry is also worsening the situation. The use of antibiotics in poultry and livestock industries for the prevention of fatal infections in chickens, cattle, pigs, sea food and farmed fishes is a common practice worldwide.^{2–4} This excessive use of antibiotics has led to mutations and possibly to resistance in bacterial strains.⁵ This emerging health threat has highlighted the urgent need for formulating innovative antimicrobial agents for the control of infections.⁶ In this context, the field of nanotechnology has rapidly evolved as a new approach to deal with the complexity of antibiotic resistance.⁷ Nanotechnology based materials such as nanoparticles (NPs) have displayed immense potential to combat the microbial infection more effectively as compared to conventional antibiotics.⁸ Among these materials, metal and metal oxide NPs are attracting much attention, as several studies suggested their superior activity toward resistant microorganisms.⁹ The most comprehensively studied particles having superior antimicrobial activity includes silver, gold, zinc oxide, copper, copper oxide, titanium dioxide and iron oxide NPs.^{10–13}

^aDepartment of Biotechnology, COMSATS University Islamabad, Abbottabad Campus, Pakistan

^bKhademhosseini's Laboratory, Center for Minimally Invasive Therapeutics (CMIT) California NanoSystems Institute, University of California Los Angeles, Los Angeles, USA

^cDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan

^dDepartment of Environmental Sciences, COMSATS University Islamabad, Abbottabad Campus, Pakistan

^eDepartment of Nanosciences and Technology, National Centre for Physics, Islamabad, Pakistan

^fDepartment of Chemical Engineering, College of Engineering, Dhofar University, Salalah, Oman

^gDepartment of Chemistry, Faculty of Science, Yazd University, Iran

^{*}Department of Biomedical Sciences, Pak-Austria Fachhochschule: Institute of Applied Sciences and Technology, Mang, Khanpur Road, Haripur, Pakistan. E-mail: fazli.wahid@fbse.paf-iast.edu.pk


Spinel ferrite (SF) are ferromagnetic compounds that are usually oxides of various transition metals, containing iron *e.g.* ZnFe_2O_4 , NiFe_2O_4 , $\text{Zn/NiFe}_2\text{O}_4$, CoFe_2O_4 , MnFe_2O_4 , and MgFe_2O_4 .^{13–15} These NPs have unique optical, electrical and magnetic properties and can easily be magnetized or demagnetized due to their soft and insulating nature. SF NPs are mostly used as magnetic, refractory and catalytic materials.¹⁶ Ferrites are used in diverse technological applications such as microelectronics, humidity sensors, microwave reflections, drug delivery system and magnetic resonance imaging (MRI).¹⁷ Moreover, ferrites are also utilized in high density data storage materials, catalyst, converters and antenna frames.¹⁴ Conjugation of ferrites and some divalent metallic ions dramatically enhance the properties of ferrites.¹⁸ The addition of metal ion to ferrite strengthens its property of coercivity.¹⁹ NiFe_2O_4 (NF) and $\text{Zn-NiFe}_2\text{O}_4$ (ZNF) NPs have gained much attention due to their diverse applications. NF NPs are applied in magnetic extraction, MRI, cell labeling, drug delivery and magnetic hyperthermia.²⁰ Likewise, Zn substituted nickel SF NPs have gained much interest due to modifiable magnetic parameters, high electromagnetic performance, and good chemical stability. Similarly, ZNF NPs have been employed in magnetic hyperthermia, MRI, drug delivery and magnetic extraction.¹⁷

Although well-reported for above mentioned potentials, substantial efforts are needed regarding its medical applications and biological activities specifically the bactericidal mechanism, biocompatibility, and wound healing abilities. It has been proposed that the existing biological features can be improved by incorporating transition metals into ferrite NPs.²¹ Linking to the stated concept, we aimed to synthesize multi-purpose NF and ZNF NPs and to observe their biocompatibility and detailed bactericidal mechanism. Biocompatibility was analyzed against human dermal fibroblast and red blood cells, whereas the mechanisms of bactericidal action were established against Gram-positive and Gram-negative strains through multiple analytical techniques. We hope that this study may provide a strong base for the use of NF and ZNF NPs as possible candidates for control of bacterial infections and improving the process of wound healing.

2. Experimental

2.1. Synthesis of nanoparticles

NF NPs were synthesized by previously reported method of co-precipitation with slight modification.²² Stoichiometric amounts of iron (10 mmol) and nickel (0.5 mmol) salts were added in 100 ml of deionized water under constant stirring until complete dissolution. Oleic acid was added to the solution at the rate of 1 drop per 25 ml. Sodium hydroxide (3 mol) solution was then added drop wise (2 ml min^{-1}) under constant stirring, until the pH become alkaline (>12). Temperature of the solution was maintained at 80°C throughout the reaction. After attaining the desired pH, the solution was centrifuged at 5000 rpm for 5 min. These precipitates were washed with enough distilled water and ethanol till neutralization, then dried at 80°C and finally annealed at 500°C to get the NF NPs.

For the synthesis of ZNF NPs, the aqueous solution of nickel, zinc and ferric chloride was prepared in fixed molar ratio of 1 : 1 : 2 of Ni/Zn/Fe. As a surfactant, 2–3 drops of oleic acid were added to each 75 ml of solution. Under constant stirring, 1.5 mol NaOH solution was added drop wise at the rate of 2 ml min^{-1} , until pH become >12 . Temperature was maintained at 80°C throughout the reaction. The solution was centrifuged at 6000 rpm and the obtained precipitates were washed with distilled water and ethanol several times until pH become neutral. In last, particles were dried at 70°C to get powder form and finally annealed at 500°C .²³

2.2. Characterization of NPs

X-ray Diffraction (XRD) technique was used for the determination of crystallite size and phase identification of synthesized nanomaterials. These analyses were carried out by using Bruker, D8 Advanced at the scan rate of $1.2^\circ/\text{min}$ in 2θ range of 10 – 80° . $\text{Cu K}\alpha$ ($\lambda = 1.54056 \text{ \AA}$) was used as radiation source and generated at 40 kV and 40 mA. Scanning electron microscopy (SEM) along with energy-dispersive X-ray spectroscopy (EDX) was used to confirm the surface morphology and elemental composition of NPs (SEM MAG: 25.0 kx, MIRA3 TESCAN Institute of space technology, ISB).²⁴

2.3. Biocompatibility

Biocompatibility studies were carried out to check the safety of NF and ZNF NPs. For this purpose, human dermal fibroblast cells (HDF) were maintained and cultured in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS) and 2% Penicillin–Streptomycin (Pen/Strep) under standard condition of 5% CO_2 and 37°C in a cell culture incubator (Thermo Fisher Scientific PA, USA). PrestoBlue assay was performed to evaluate the cell metabolic activity as per previously reported protocol.²⁵ Briefly, the HDF cells were trypsinized with 0.5% trypsin–EDTA, followed by counting with hemocytometer, centrifuged and re-suspended the cell pellet in DMEM complete media. Afterwards, cells ($5000 \text{ cells per ml}$) were seeded in 48 well culture plates for 24 h. Then, different concentrations (1000 , 500 , 250 , 125 and $62 \mu\text{g ml}^{-1}$) of both NF and ZNF NPs were added and incubated for different time periods. PrestoBlue assay was performed on day 1 and day 5 and fluorescent intensity was measured using micro plate reader (excitation 530 nm , emission at 570 nm , BioTek UV/VIS synergy 2, VT, USA). Cell viability was assessed *via* live/dead fluorescence assay. Briefly, cells on day 5 of NPs treatment were incubated for 20 min with 1 ml of staining solution containing ethidium homodimer-1 ($20 \mu\text{l}$) and calcein AM ($5 \mu\text{l}$) in Dulbecco's Phosphate Buffer Saline (DPBS). Finally, the images were taken using fluorescence microscopy (Axio Observer 5, Zeiss Germany) with excitation/emission wavelength of $528/617$ for ethidium homodimer-1 and $528/617$ for calcein.

Moreover, hemolysis assay was performed according to the ASTM E2524-08 standard protocol to evaluate the hemocompatibility of the NPs.²⁶ For this purpose, whole human blood was acquired from ZenBio and used according to the



institutionally (UCLA) approved safety protocols. Blood was stored in heparinized tubes, refrigerated, and used in the assay not later than 48 h. Concentration of the hemoglobin in the blood was estimated by Drabkin's reagent, using a standard curve generated on different concentrations of pure human hemoglobin (1000–62 $\mu\text{g ml}^{-1}$). The blood was diluted with DPBS to adjust the hemoglobin concentration to $10 \pm 2 \text{ mg ml}^{-1}$. The required concentrations of NPs were added in Eppendorf tubes containing 800 μl DPBS, followed by adding 100 μl of the diluted blood. Polyethylene glycol (PEG) (4.4% v/v in DPBS) and triton X-100 (1% v/v in DPBS) treated lysed red blood cells were used as positive control and diluted blood served as negative control. All the samples were incubated in a water bath (37 °C) for $3 \text{ h} \pm 15 \text{ min}$, followed by centrifugation at 14 000 rpm for 15 min. The supernatant (100 μl) was transferred to a 96-well plate containing equal volume of Drabkin's reagent and was kept in dark on the shaker (100 rpm) for 15 min. The absorbance was recorded at 540 nm against the reagent blank by using a microplate reader (540 nm, BioTek UV/VIS Synergy 2, VT, USA). The concentration of cell-free hemoglobin in each sample was estimated using the standard curve. Eventually, hemolysis (%) was determined by the following equation;

$$\text{Hemolysis}(\%) = \frac{\text{hemoglobin concentration in sample}}{\text{total blood hemoglobin}(\sim 10 \text{ mg ml}^{-1})} \times 100$$

2.4. Antimicrobial activity

All the bacterial strains *i.e.* *Escherichia coli* (*E. coli*) (ATCC 15224), *Pseudomonas aeruginosa* (*P. aeruginosa*) (ATCC-15442), *Klebsiella pneumoniae* (*K. pneumoniae*) B5055, *Salmonella typhi* (*S. typhi*) (ATCC 14028) and *Staphylococcus aureus* (*S. aureus*) (ATCC 6538) were kindly provided by Department of Pharmacy, Quaid-i-Azam University, Pakistan. The methicillin-resistant *Staphylococcus aureus* (MRSA) was donated by Dr Shujaat Ali Khan, Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Pakistan. Various drug sensitivity tests were performed by Shujaat *et al.* to confirm that clinical isolate of MRSA is resistant to antibiotics.²⁷

The antimicrobial activity of synthesized NPs was performed using agar well diffusion method with some modifications.^{28–31} For this assay, inoculums of selected strain were used with optical density (OD) between 0.1–0.5 at 600 nm. The inoculum was spread evenly on nutrient agar plates, wells of 70 mm² diameter were bored and selected concentrations of NPs solution was added into the well. Selected concentrations of NF and ZNF were 1000 $\mu\text{g ml}^{-1}$, 600 $\mu\text{g ml}^{-1}$, 300 $\mu\text{g ml}^{-1}$, 100 $\mu\text{g ml}^{-1}$ and 50 $\mu\text{g ml}^{-1}$. The plates were incubated for 24 h at 37 °C. Silver sulfadiazine was used as positive control and dimethyl sulfoxide (DMSO) as a vehicle control. Zone of inhibitions were measured after 24 h of treatment.

Moreover, live dead assay was performed with representative Gram-negative strain *E. coli* and Gram-positive *S. aureus*. Concentrations of 250 $\mu\text{g ml}^{-1}$ for NF and 125 $\mu\text{g ml}^{-1}$ for ZNF were used for live dead assay, as these concentrations are biocompatible with human cells. Live and dead bacterial cells

assessment was carried out with live/dead back light L-7012 (Invitrogen, USA) using fluorescence light microscopy as previously reported with little modifications.³² Briefly, the overnight grown cultures of *E. coli* and *S. aureus* were adjusted to concentration of $1 \times 10^5 \text{ CFU ml}^{-1}$. The bacterial cells were treated with the selected dose of NF and ZNF NPs for 8 h. Tetracycline treated bacterial cell served as positive control. At the end, treated cells were collected and centrifuged at 10 000 rpm for 5 min at 4 °C. Resultant pellet was washed with phosphate buffer saline (PBS) and stained with SYTO 9 and propidium iodide (PI) for 15 min under dark conditions. The stained bacterial cells were observed under fluorescence microscope to record images. Fluorescence from PI was detected using a filter with excitation wavelength of 540–580 nm and an emission filter of 600–660 nm. Fluorescence from SYTO9 was detected using a filter with excitation wavelength of 465–495 nm and an emission filter of 515–555 nm (Axio Observer 5, zeiss, Germany).

2.5. Mechanism of action of NF and ZNF

The mechanisms of bactericidal action of synthesized NPs were analyzed by fluorescence-activated cell sorting (FACS) analysis, Bio-Rad protein assay and dichlorofluorescein diacetate dye method (DCFDA). The selected doses for this analysis were same as that of live/dead assay *i.e.* 250 $\mu\text{g ml}^{-1}$ for NF and 125 $\mu\text{g ml}^{-1}$ for ZNF. The *E. coli* was selected as a representative strain from Gram-negative and *S. aureus* from Gram-positive group.

2.5.1. Effects of NPs on the membrane permeability. The effects of NPs on bacterial membrane was investigated *via* FACS analysis as previously reported with slight modifications.³³ Briefly, short log-phase bacterial culture of *E. coli* and *S. aureus* were incubated for 12 h with NF and ZNF at a dose of selected concentration, in LB growth medium containing fluorescein isothiocyanate fluorescent dye (FITC) (0.05%). Tetracycline (5 mg ml^{-1}), a potent membrane permeabilization agent, was used as a positive control. Finally, cells were washed several times to remove the excess FITC present in the media. Bacterial membranes are impermeable to FITC dye in normal conditions. Membrane disruption of bacteria by some agent would only allow FITC to enter the cell and give green fluorescence.^{34–36} The emission of intense green fluorescence indicates the membrane damage. The fluorescence microscopic images were taken with excitation and emission wavelength of 491 nm and 516 nm, respectively (Axio Observer 5, zeiss, Germany).

2.5.2. Effects of NPs on bacterial protein leakage. Bio-Rad Protein assay was used to check bacterial protein leakage by NF and ZNF NPs treatment. For this purpose, the overnight broth cultures of *E. coli* and *S. aureus* were washed twice with normal saline *via* centrifugation (10 000 rpm for 15 min) followed by re-suspending in saline. Suspensions of *E. coli* and *S. aureus* were treated separately with 250 $\mu\text{g ml}^{-1}$ of NF and 125 $\mu\text{g ml}^{-1}$ of ZNF NPs for 8 h. Tetracycline treated bacterial cells were used as positive control, while untreated bacterial cells were considered as negative control. After treatment, each bacterial suspension was centrifuged at 12 000 rpm for 15 min



and the obtained supernatant was analysed for protein estimation using Bio-Rad Protein assay kit (Bradford method).³⁷ The protein concentration was estimated from standard curve that was established using known concentrations of bovine serum albumin (BSA).

2.5.3. Reactive oxygen species (ROS) generation. The intracellular ROS generation by NF and ZNF NPs was measured *via* DCFDA dye method.³⁸ This dye can be oxidized by intracellular ROS species to 2',7'-dichlorofluorescein (DCF), a highly fluorescent compound, which provides quantitative measurement of ROS formation. For this purpose, *E. coli* and *S. aureus* were individually treated with 250 $\mu\text{g ml}^{-1}$ of NF and 125 $\mu\text{g ml}^{-1}$ of ZNF NPs for 8 h. At the end of treatment, bacterial cells were centrifuged at 9000 rpm for 5 min. The obtained bacterial pellet was suspended in 30 $\mu\text{g ml}^{-1}$ DCFDA dye solution in PBS and incubated in the dark at 37 °C for 30 min. After incubation, cells were centrifuged and re-suspended in 450 μl fresh PBS, and fluorescence was measured at excitation/emission wavelength of 485/528 nm using plate reader (Bio Tek UV/VIS Synergy 2, VT, USA).

2.6. *In vitro* scratch assay

In vitro scratch method was performed to evaluate the wound healing potentials of the NPs. For this, *in vitro* cell migration assay were performed as per reported protocol.³⁹ Briefly, primary mouse embryonic fibroblast NIH-3T3 cells were seeded with DMEM containing 10% FBS and 1% pen/strep in 6-well plate at the cell density of 10^6 cell per ml and kept in CO₂ incubator at 37 °C. When monolayer of cells covered the wells, a scratch was made with 200 μl pipette tips followed by washing cells with FBS free DMEM, twice. Next, the sterilized solution of required concentration of NF and ZNF NPs in DMEM (without FBS) were added to the wells. A control group was also run in which cells were cultured in DMEM (without FBS) and left untreated. After being cultured for 0 and 18 h, the images of cells were taken with fluorescence microscope in bright field (Axio Observer 5, zeiss, Germany). In addition, the original and final width of the scratch was measured with ImageJ software by using MRI wound healing tool and percentage of scratch shrinkage was calculated with the following formula:

$$\% \text{ of scratch shrinkage} = 100 \times \frac{\text{original width} - \text{final width}}{\text{original width}}$$

2.7. Statistical analysis

Where necessary, data was taken in triplicates and their mean standard deviation was measured with the standard deviation tool of Microsoft excel 2010. The *p* value was measured by using Student *t*-test, *p* ≤ 0.05 was considered significant.

3. Results and discussion

3.1. Characterization of NPs

3.1.1. XRD analysis. The crystal structures of the synthesized NPs (NF and ZNF) were confirmed by XRD analysis




Fig. 1 X-ray diffraction patterns of (a) NF, (b) ZNF NPs.

shown in Fig. 1. The diffraction patterns indicated the synthesis of pure phase NPs. Diffraction peaks of NF (Fig. 1a) and ZNF NPs (Fig. 1b) revealed typical reflection of (220), (311), (400), (422), (511) and (440) planes that indicate the formation of pure phase cubic spinel structure. The entire diffraction peaks of NF NPs matched with the XRD pattern of the previously reported literature.^{22,40,41} Likewise, the diffraction pattern of ZNF NPs also matched with the previously reported data.^{23,42} Average crystallite size of NF and ZNF were calculated using Scherer's formula and found to be 25 and 54 nm, respectively.

3.1.2. FE-SEM and EDX analysis. The SEM and EDX pattern of NF and ZNF NPs showed the average particles size of 49 and 46 nm, respectively. The particles were spherical in shape, homogenously distributed with little agglomerates due to their magnetic property as shown in Fig. 2a–d. The elemental composition observed through EDX analysis further stamped the successful synthesis. Our findings are in accordance with previously reported studies.^{43,44}




Fig. 2 Nanoparticle characterization using Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray analysis (EDX). Average particle size of (a) NF is 49 nm ± 3.8, (b) ZNF is 47 nm ± 2.5. EDX analysis of (c) NF, (d) ZNF showed their appropriate elemental composition.



3.2. Biocompatibility

Despite of the antimicrobial potential and diverse biological applications of various NPs, their use as a therapeutic agent is limited because of their toxicity.⁴⁵ In the current study, the biocompatibility of NF and ZNF NPs with HDF cells was analyzed *via* PrestoBlue assay. As the PrestoBlue reagent is a resazurin-based solution that utilizes the reducing power of the living cells to quantitatively measure cell metabolic activity. If the cells are alive, these maintain a reducing environment in cytosol.⁴⁶ The results showed that NF and ZNF NPs were not cytotoxic to HDF cells at concentration of equal or below 250 and 125 $\mu\text{g ml}^{-1}$, respectively as shown in Fig. 3C and J. It was also observed that at safer concentrations, the fibroblast cells proliferate significantly with the passage of time (Fig. 3C–E, J and K). To the best of the literature search, this is the first study to report the biocompatibility of NF and ZNF with HDF cells. However, earlier studies reported that Vero cells (monkey kidney epithelial cells) were more than 90% viable when treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs.⁴⁷ The results also revealed that the cell viability significantly decreased at higher doses and cells seems to be almost dead (Fig. 3A, B, G and H). As more than 50% cells were died due to arrest of metabolic activities at higher concentration (Fig. 3M and N); therefore 250 $\mu\text{g ml}^{-1}$ of NF and 125 $\mu\text{g ml}^{-1}$ of ZNF NPs were considered the safer concentrations and chosen for antimicrobial and other experimentations.

NPs induce effects on human erythrocytes through different mechanisms. The most common mechanisms include hemolysis (rupture of erythrocytes membrane) and generation of free radical that can further lead to erythrocytes apoptosis.⁴⁸ Other effects of NPs on human erythrocytes include morphological

changes, oxidative stress induction and alteration of enzymatic activities. Therefore, hemolytic activity of NF and ZNF NPs were evaluated at different concentrations (1000, 500, 250, 125 and 62 $\mu\text{g ml}^{-1}$) to find out the best hemocompatible dose. Results showed that there was no significant hemolysis at any tested concentration. It can be seen in Fig. 4B and D that there is no significant difference between the negative control and NPs treated group at all concentrations. However, there is significant difference in positive control and treated groups. In Fig. 4A and B, no hemoglobin was observed in supernatant of NPs treated samples and negative control, while hemoglobin was present in supernatant of positive control, which indicated that no hemolysis was observed in any sample except for positive control. A previous study reported that NF NPs were biocompatible at 200 $\mu\text{g ml}^{-1}$ but ZNF induced hemolysis at 200 $\mu\text{g ml}^{-1}$.²⁰ Some other studies reported that iron oxide NPs induced reduction in hemoglobin concentration in rat⁴⁹ and produced hemolysis and oxidative stress in human⁵⁰

3.3. Antibacterial activities of NF and ZNF

The antibacterial activities of the NF and ZNF NPs were evaluated against four Gram-negative bacteria including *E. coli*, *P. aeruginosa*, *Klebsiella* and *S. typhi* and two Gram-positive bacteria *i.e.*, *S. aureus* and MRSA. As shown in Table 1, the NF and ZNF NPs exhibited dose dependent antibacterial activity against the selected microbial strains. The ZNF NP was more active against *E. coli*, *Klebsiella*, *S. typhi* and *S. aureus*. Similarly, NF was more potent against *P. aeruginosa* and MRSA. Previously, similar antimicrobial results were reported for NF NPs;^{43,51} however, there is no reported literature available for antimicrobial activity of ZNF. The structure and chemical composition of cell wall are different in Gram-negative and Gram-positive bacteria. The cell wall of Gram-negative bacteria (*e.g.* *E. coli*) mainly consists of lipid A, lipopolysaccharide and




Fig. 3 Fluorescent microscopic images of human dermal fibroblast cells stained with ethidium homodimer-1 (20 μl) and calcein AM (5 μl) in DPBS at 500 \times magnification. Live cells can be seen as green and dead as red. HDF cells were treated with NF NPs at a concentration of (A) 1000 $\mu\text{g ml}^{-1}$ (B) 500 $\mu\text{g ml}^{-1}$ (C) 250 $\mu\text{g ml}^{-1}$ (D) 125 $\mu\text{g ml}^{-1}$ (E) 62 $\mu\text{g ml}^{-1}$ (F) 0 $\mu\text{g ml}^{-1}$ (control) and ZNF NPs concentrations of (G) 1000 $\mu\text{g ml}^{-1}$ (H) 500 $\mu\text{g ml}^{-1}$ (I) 250 $\mu\text{g ml}^{-1}$ (J) 125 $\mu\text{g ml}^{-1}$ (K) 62 $\mu\text{g ml}^{-1}$ (L) 0 $\mu\text{g ml}^{-1}$ (control). The percent metabolic activity of HDF cells at day 1 and 5 after treatment with different concentrations of (M) NF NPs and (N) ZNF NPs. Error bars represent the standard deviation, and (*) represent significance of reduction of % metabolic activities vs. control at different concentration with * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.




Fig. 4 Hemocompatibility of NF and ZNF NPs, (A) photograph of hemolysis assay to detect presence of hemoglobin in the supernatant of NF NPs treated sample, (B) hemolysis percentage of NF NPs treated samples along with positive and negative control, (C) photograph of hemolysis assay to detect presence of hemoglobin in the supernatant of ZNF treated sample, and (D) hemolysis percentage of ZNF NPs treated samples along with positive and negative control samples. Positive control was PEG and triton X-100 lysed blood cells, negative control was untreated blood. The values presented in the graph are mean \pm SD of triplicate. Hemolysis in NPs treated samples was significantly lower in comparison to positive control (*** $p \leq 0.001$).



Table 1 Zones of inhibition of pathogenic bacteria after treatment with NF and ZNF NPs^a

Conc. ($\mu\text{g ml}^{-1}$)	<i>E. coli</i>		<i>P. aeruginosa</i>		<i>K. pneumoniae</i>		<i>S. typhi</i>		<i>S. aureus</i>		MRSA	
	NF	ZNF	NF	ZNF	NF	ZNF	NF	ZNF	NF	ZNF	NF	ZNF
1000	12 \pm 0.3	12 \pm 0.2	12 \pm 0.5	12 \pm 0.5	12 \pm 0.4	13 \pm 0.2	11 \pm 0.1	12 \pm 0.4	14 \pm 0.2	14 \pm 0.4	12 \pm 0.5	13 \pm 0.5
600	11 \pm 0.4	12 \pm 0.9	11 \pm 0.1	11 \pm 0.2	11 \pm 0.3	12 \pm 0.2	11 \pm 0.5	12 \pm 0.2	14 \pm 0.3	14 \pm 0.4	12 \pm 0.2	12 \pm 0.3
300	10 \pm 0.5	11 \pm 0.5	10 \pm 0.1	9 \pm 0.5	10 \pm 0.3	10 \pm 0.2	10 \pm 0.4	11 \pm 0.1	13 \pm 0.1	11 \pm 0.5	12 \pm 0.5	12 \pm 0.5
100	10 \pm 0.3	9 \pm 0.5	10 \pm 0.1	9 \pm 0.2	10 \pm 0.3	9 \pm 0.5	10 \pm 0.6	10 \pm 0.1	13 \pm 0.4	10 \pm 0.7	11 \pm 0.2	11 \pm 0.5
50	10 \pm 0.2	9 \pm 0.3	9 \pm 0.2	8 \pm 0.1	9 \pm 0.1	9 \pm 1.3	9 \pm 0.4	8 \pm 0.5	12 \pm 0.9	10 \pm 0.1	10 \pm 0.1	10 \pm 0.6
PC	13 \pm 0.1	14 \pm 0.5	16 \pm 0.2	19 \pm 2	13 \pm 0.4	14 \pm 0.5	17 \pm 0.6	15 \pm 0.4	18 \pm 1.9	18 \pm 1.2	14 \pm 0.9	16 \pm 1
VC	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0

^a NF = NiFe₂O₄, ZNF = Zn-NiFe₂O₄, PC = positive control, VC = vehicle control.

peptidoglycan; however, Gram-positive bacteria (e.g. *S. aureus*) cell wall comprises mainly of peptidoglycan.⁵² The difference in antibacterial activity of NF and ZNF NPs against various bacterial strains may be due to differences in cell wall composition and variation in interaction with membrane at molecular and cellular level. Moreover, particle size, crystal structure, morphology, surface area and charge also play a significant role in antibacterial activity.^{53–55}

To further confirm the antimicrobial activity, live dead assay was performed against the representative Gram-negative (*E. coli*) and Gram-positive (*S. aureus*) bacterial strains. The green fluorescent dye SYTO 9 can only bind with the viable and healthy bacterial cells, whereas, PI dye binds to damaged and/or dead cells, and hence, emit red fluorescence.⁵⁶ In Fig. 5A (*E. coli* without any treatment) and Fig. 5E (*S. aureus* without treatment) serves as negative control. The intense green fluorescence

shows the viable *E. coli* (Fig. 5A) and *S. aureus* (Fig. 5E) cells. Fig. 5B and F showed maximum dead cells, which represented the positive control of *E. coli* and *S. aureus* cells in the study. Whereas, in Fig. 5C red fluorescence show that majority of the *E. coli* cells treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs were dead. Same results were observed for *S. aureus* (Fig. 5G) when treated with the same concentration. Fig. 5D (*E. coli*) and Fig. 5H (*S. aureus*) also show that majority of the bacterial cells are dead when treated with 150 $\mu\text{g ml}^{-1}$ of ZNF NPs. The observed results indicated the prominent antimicrobial activity of NF and ZNF NPs at biocompatible doses. These results are in accordance with the previous literature that SF NPs possess broad-spectrum antibacterial activities against Gram-positive and Gram-negative bacterial strains.^{55,57,58} In one such study, Elayakumar *et al.*, investigated that Ce³⁺ doped CuFe₂O₄ caused inhibition of *S. aureus* and *Klebsiella pneumoniae*.⁵⁵ Another study revealed that ZnFe₂O₄ and Ag hybrid nanostructures effectively halted the growth of *Candida albicans*.⁵⁹ Similarly, CoFe₂O₄ NPs efficiently killed *Bacillus subtilis*, *S. aureus*, *E. coli* and *P. aeruginosa*,⁵⁷ while MgFe₂O₄ NPs exhibited good antibacterial property against *P. aeruginosa*, *E. coli*, *S. aureus* and *Serratia marcescens*.⁵⁸ Other studies reported that NiFe₂O₄ based nanocomposite possesses prominent antibacterial activities against *E. coli* and *S. aureus*,⁶⁰ while nickel substituted copper ferrite displayed better antimicrobial activity against *E. coli*, *K. pneumoniae*, *S. aureus*, and *B. subtilis*.⁶¹

Furthermore, the size of NPs greatly influences their biomedical application.⁶² Previously, Elsabahy and Wooley suggested that intermediate sizes (20–200 nm) of NPs have the greater potential for biomedical applications.⁶³ ZnO NPs with particle size of 50 \pm 5 nm exhibited good antimicrobial activity against *Escherichia coli* (8 and 16 mg ml⁻¹) and *Staphylococcus aureus* (4 and 8 mg ml⁻¹), respectively.⁶⁴ Likewise, ZnO NPs coated with crustacean immune molecule having a particle size of 20–50 nm restrained the growth of *S. aureus* and *P. vulgaris*.⁶⁵ Similarly, our synthesised NF and ZNF NPs have a particle size of 49 \pm 3.8 and 47 \pm 2.5 nm, respectively, have potent antimicrobial activity even at a concentration of 50 $\mu\text{g ml}^{-1}$. It was noticed that NF and ZNF NPs acted on both human and bacterial cells, but the toxicity to human cells was low or negligible in comparison to bacterial cells when the same concentration was used. A previous study also reported similar




Fig. 5 Fluorescent microscopy images of *E. coli* and *S. aureus* after treatment with NPs. (A) *E. coli* without any treatment (negative control), (B) *E. coli* treated with tetracycline (positive control), (C) *E. coli* treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs, (D) *E. coli* treated with 125 $\mu\text{g ml}^{-1}$ of ZNF NPs, (E) *S. aureus* without treatment (negative control), (F) *S. aureus* treated with tetracycline (positive control), (G) *S. aureus* treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs and (H) *S. aureus* treated with 125 $\mu\text{g ml}^{-1}$ of ZNF NPs. Percent dead cells of (I) *E. coli* and (J) *S. aureus* after treatment with different concentration of NPs. Experiments were performed in triplicate. The percent dead cells of *E. coli* and *S. aureus* was significantly higher in NP treated groups and positive control (PC) as compared to negative control (NC), (** $p \leq 0.01$, *** $p \leq 0.001$).



results.⁶⁶ The different effects on human and bacterial cells might be due to the alterations in the cell membrane structures of mammalian and bacterial cells. The existence of endocytic machinery, and multiple intracellular compartments in human cells also prevent the entry of NPs within the cell. Thus, keeping the NPs away from the direct interaction with the important molecules present within the human cells. Furthermore, NF and ZNF NPs have negative surface charge at neutral pH that make them less toxic in comparison to positive charge NPs⁶⁷

3.4. Mechanism of action of NF and ZNF

3.4.1. Effects of NPs on the membrane permeability. It is important to understand the mechanism of action of any antimicrobial agent; therefore, the effects of NPs on the bacterial membrane permeability were investigated. Bacterial membrane has an important role in its structural and functional integrity. Therefore, minute changes in the structural integrity of cell membrane can adversely affect cell metabolism that may lead to cell death.⁶⁸ Bacterial cells are impermeable to FITC (fluorescent dye) under normal conditions, but when membranes are destabilized then this dye can easily penetrate the cells. In the current study, an intense fluorescence was observed after *E. coli* and *S. aureus* cells were treated with NF at concentration of 250 $\mu\text{g ml}^{-1}$ as shown in Fig. 6C and G. Similar results were observed for ZNF NPs at concentration of 125 $\mu\text{g ml}^{-1}$ (Fig. 6D and H). This indicated that NF and ZNF NPs treatment damaged the bacterial membrane. Tetracycline, a potent membrane permeabilization agent, was used as a positive control and caused membrane disruption of both *E. coli* and *S. aureus* (Fig. 6B and F). Negative control (untreated cells) did not show any prominent green fluorescence (Fig. 6A and E). Previously, similar results were reported for silver NPs, which induced membrane damaged in both Gram-negative and Gram-positive bacteria.^{32,69} Moreover, Arakha and coworkers reported that iron oxide NPs causes bacterial membrane depolarization upon

interaction.⁷⁰ Similarly, Wang and his colleagues observed that CoFe_2O_4 NPs also disrupt the bacterial membrane.^{71,72} Another study reported that CuFe_2O_4 nano sheets induced damage to bacterial membrane.⁷³ However, there was no reported literature about the effects of NF and ZNF NPs on bacterial membrane. Therefore, from the current results it can be suggested that the synthesized NF and ZNF NPs disrupted the cell membrane that led to the bacterial cell death.⁷⁴ Surface charges play an important role in the reactivity of NPs with the living cells. The zeta potential, surface charge of NF and ZNF NP was reported -10 mv at neutral pH.^{75,76} According to the literature survey, the essential condition to improve the antibacterial efficiency of any particle is to have a positive particle surface charge that allows efficient electrostatic interaction with the negative charges of the bacterial cell wall.⁷⁷ This expected effect was obviously contrasted with our experimental data and represents a further important advantage of our antibacterial NPs in terms of safety in mammalian cells and tissues, assuming that cationic NPs are more cytotoxic than those with neutral or negative surface charge.⁷⁸ However, detailed elucidation of negative charge particle binding to bacterial cells is still lacking. The efficient antimicrobial activity of the synthesized NPs is essentially associated to a unique character of the NPs in biological systems, which allows us to assume the occurrence of effective interactions with bacterial membranes and sustained intracellular release of ROS. In particular, the chemico-physical properties of NPs allow for their interaction with the surface of the bacterial cell by altering the structure therein, thus favoring its permeability and subsequent cell death. Similar results have been previously reported for negative charged AgNPs that showed potent antimicrobial activity.⁷⁹

3.4.2. Effects of NPs on bacterial protein leakage. The membrane damage may cause the leakage of mineral, protein and genetic material; therefore the effects of NF and ZNF NPs on protein leakage was also investigated. As shown in Fig. 7A and B, the NF NPs at the dose of 250 $\mu\text{g ml}^{-1}$ caused the maximum protein leakage of 0.9 and 0.7 $\mu\text{g ml}^{-1}$ from *E. coli* and *S. aureus*, respectively.

Similarly, ZNF NPs, at the dose 125 $\mu\text{g ml}^{-1}$, showed protein leakage of 1.1 and 0.7 $\mu\text{g ml}^{-1}$ from *E. coli* and *S. aureus*, respectively (Fig. 7A and B). The protein leakage of NPs treated groups was significantly higher as compared to control groups. Previously, similar results were reported for cobalt ferrite;⁸⁰




Fig. 6 Fluorescent microscopy images of *E. coli* and *S. aureus* showing the influx of FITC after treatment with NPs and tetracycline (positive control). (A) Untreated *E. coli* (negative control), (B) *E. coli* treated with tetracycline, (C) *E. coli* treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs, (D) *E. coli* treated with 125 $\mu\text{g ml}^{-1}$ of ZNF NPs, (E) untreated *S. aureus* (negative control), (F) *S. aureus* treated with tetracycline, (G) *S. aureus* treated with 250 $\mu\text{g ml}^{-1}$ of NF NPs and (H) *S. aureus* treated with 125 $\mu\text{g ml}^{-1}$ of ZNF NPs. Tetracycline, NF and ZNF NPs induced membrane damaged to both selected strains of Gram-positive and Gram-negative bacteria.




Fig. 7 The effects of NF and ZNF NPs on protein leakage from (A) *E. coli* and (B) *S. aureus* after 8 h of treatment at the mentioned concentrations. All experiment were performed in triplicate and data are presented with \pm SD. * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$ were considered statistically significant.



however, no study reported the effects of NF and ZNF NPs on protein leakage. It is important to note that the difference in the protein leakage profile of Gram-positive and Gram-negative bacteria might be due to the thickness of peptidoglycan layer of bacterial cell wall. Peptidoglycan layer provide protection to bacteria against antibacterial agents like antibiotics, toxins, chemicals, enzymes and NPs.⁸¹ Similarly, Steffy *et al.*, found that protein leakage was higher in Gram-negative bacteria compared to Gram-positive bacteria.⁸²

3.4.3. Effects of NPs on ROS generation. ROS production is an indicator of the oxidative stress in the cells. Therefore, there is a direct relation between ROS production and bacterial cell death.⁸³ Previous studies have shown that NPs could cause generation of free radicals within microbial cells, which ultimately lead to cell death.⁸⁴ In the current study, ROS production was investigated in *E. coli* and *S. aureus* after 8 h treatment with NF (250 $\mu\text{g ml}^{-1}$) and NF (125 $\mu\text{g ml}^{-1}$) NPs, individually. It was observed that ROS level was significantly increased in treated groups as compared to untreated negative control group (Fig. 8A and B).

The H_2O_2 treatment was considered as positive control. It was interesting that NPs generated more ROS than H_2O_2 in *E. coli* and less in *S. aureus*. The group without treatment was considered as negative control group. A previous study reported that Ni doped CoFe_2O_4 NPs also generate ROS in bacterial cell.⁸⁵ Likewise, a study reported that ZnFe_2O_4 NPs generate ROS, which can be used in photodynamic therapy.⁸⁶ Hence, it can be concluded that NF and ZNF NPs exert antimicrobial activity through free radicals (ROS) production that generate oxidative stress in bacteria. The oxidative stress causes breakdown of cell membrane with subsequent leakage of cytoplasmic material (protein) thus resulting in distortion of metabolic activities and consequently the cell death.

3.5. Scratch assay

Scratch assay is the most convenient method to illustrate the wound healing potential of drug, molecule or NPs.⁸⁷ Therefore, *in vitro* scratch assay was performed to find the wound healing potentials of NF and ZNF NPs. The results showed that the proliferation and migration of cells in artificial wound area was significantly higher in NF and ZNF NPs treatment as compare to control (Fig. 9A–C). Both the NPs promoted the migration of




Fig. 9 *In vitro* scratch assay (A) negative control after 0 h and 18 h of cell incubation, (B) photographs after 0 h and 18 h of cells treated with NF, (C) photographs after 0 h and 18 h of cells treated with ZNF NPs, (D) percent scratch shrinkage of treated and control sample. The experiments were performed in triplicates, and data are presented as \pm SD whereas, * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$ were considered statistically significant.

fibroblasts, but the restoration of cellular density was faster in ZNF NPs than NF NPs. Percent scratch shrinkage of both NF and ZNF NPs treated sample was significantly higher than control (untreated) as shown in Fig. 9D. Previous study reported similar results for silver NPs loaded collagen/chitosan scaffolds.^{87,88} It was observed that silver NPs loaded collagen/chitosan scaffolds increased the fibroblast migration using *in vitro* scratch assay. Previously, no data is available for NF and ZNF NPs wound healing potential; therefore further animal studies can be performed to fully investigate the effect of NF and ZNF NPs on wound healing process.

4. Conclusions

It can be concluded from the results that the prepared NF and ZNF NPs were homogeneous with uniform elemental distribution. The prepared NPs were compatible with human dermal and blood cells, which suggested that these can be potential candidates for biomedical applications. The NPs were active against both Gram-positive and Gram-negative bacterial strain at biocompatible doses. It can be suggested that NF and ZNF NPs causes bacterial cell death *via* membranes disruption, protein leakage and ROS generation. The *in vitro* scratch assay revealed that these NPs have strong wound healing potentials. In summary, NF and ZNF NPs can act as potent antimicrobial nano-drugs against infectious organisms and may also be used in wound healing formulations.

Conflicts of interest

There is no conflict to declare.

Acknowledgements

We acknowledge the Higher Education Commission of Pakistan for providing International Research Support Initiate Program (IRSIP) facility. We would also like to thank Professor Ali Khademhosseini research group at California NanoSystems Institute, University of California Los Angeles, USA for providing cell culture lab facility.




Fig. 8 Generation of intracellular ROS by NF and ZNF NPs after 8 h of treatment in (A) *E. coli* and (B) *S. aureus*. H_2O_2 treated cells were taken as positive control (PC) and cells without treatment as negative control (NC). All experiments were performed in triplicates, and data are presented as \pm SD. * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$ were considered as statistically significant.



Notes and references

- 1 M. Unemo, C. del Rio and W. M. Shafer, *Microbiol. Spectrum*, 2016, **10**, 213–237.
- 2 G. M. Steede, C. Meyers, N. Li, E. Irlbeck and S. Gearhart, *J. Appl. Commun. Res.*, 2018, **102**(4), 49–61.
- 3 V. Economou and P. Gousia, *Infect. Drug Resist.*, 2015, **8**, 49–61.
- 4 B. M. Marshall and S. B. Levy, *Clin. Microbiol. Rev.*, 2011, **24**, 718–733.
- 5 I. Levin-Reisman, I. Ronin, O. Gefen, I. Braniss, N. Shores and N. Q. Balaban, *Science*, 2017, **355**, 826–830.
- 6 E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, C. Pulcini, G. Kahlmeter, J. Kluytmans and Y. Carmeli, *Lancet Infect. Dis.*, 2018, **18**, 318–327.
- 7 Y. Liu, L. Shi, L. Su, H. C. van der Mei, P. C. Jutte, Y. Ren and H. J. Busscher, *Chem. Soc. Rev.*, 2019, **48**, 428–446.
- 8 A. Rai, M. Comune and L. Ferreira, in *Antibacterial Drug Discovery to Combat MDR*, Springer, 2019, pp. 605–633.
- 9 N.-Y. Lee, P.-R. Hsueh and W.-C. Ko, *Front. Pharmacol.*, 2019, **10**, 1153.
- 10 N. A. Villegas, S. Ravetti, J. M. Bermúdez, A. G. Cid, D. A. Allemandi and S. D. Palma, in *Materials for Biomedical Engineering*, Elsevier, 2019, pp. 383–407.
- 11 S. Rehman, R. Jermy, S. M. Asiri, M. A. Shah, R. Farooq, V. Ravinayagam, M. A. Ansari, Z. Alsalem, R. Al Jindan and Z. Reshi, *RSC Adv.*, 2020, **10**, 32137–32147.
- 12 S. Rehman, R. Farooq, R. Jermy, S. M. Asiri, V. Ravinayagam, R. A. Jindan, Z. Alsalem, M. A. Shah, Z. Reshi and H. Sabit, *Biomolecules*, 2020, **10**, 622.
- 13 S. Rehman, S. M. Asiri, F. A. Khan, B. R. Jermy, V. Ravinayagam, Z. Alsalem, R. Al Jindan and A. Qurashi, *Sci. Rep.*, 2020, **10**, 1–9.
- 14 K. K. Kefeni, T. A. Msagati, T. T. Nkambule and B. B. Mamba, *Mater. Sci. Eng., C*, 2019, 110314.
- 15 S. Rehman, M. A. Ansari, M. A. Alzohairy, M. N. Alomary, B. R. Jermy, R. Shahzad, N. Tashkandi and Z. H. Alsalem, *Processes*, 2019, **7**, 714.
- 16 F. da Silva, J. Depeyrot, A. Campos, R. Aquino, D. Fiorani and D. Peddis, *J. Nanosci. Nanotechnol.*, 2019, **19**, 4888–4902.
- 17 H. Ghayour, M. Abdellahi, N. Ozada, S. Jabbrzare and A. Khandan, *J. Phys. Chem. Solids*, 2017, **111**, 464–472.
- 18 A. Ashour, A. I. El-Batal, M. A. Maksoud, G. S. El-Sayyad, S. Labib, E. Abdeltwab and M. El-Okr, *Particuology*, 2018, **40**, 141–151.
- 19 X. Zhao, A. Sun, W. Zhang, L. Yu, Z. Zuo, N. Suo, X. Pan and Y. Han, *J. Mater. Sci.: Mater. Electron.*, 2019, 1–17.
- 20 N. L. Martínez-Rodríguez, S. Tavárez and Z. I. González-Sánchez, *Toxicol. in Vitro*, 2019, **57**, 54–61.
- 21 N. Sanpo, C. C. Berndt, C. Wen and J. Wang, *Acta Biomater.*, 2013, **9**, 5830–5837.
- 22 K. Maaz, S. Karim, A. Mumtaz, S. Hasanain, J. Liu and J. Duan, *J. Magn. Magn. Mater.*, 2009, **321**, 1838–1842.
- 23 I. Gul, W. Ahmed and A. Maqsood, *J. Magn. Magn. Mater.*, 2008, **320**, 270–275.
- 24 A. Madni, R. Khan, M. Ikram, S. Naz, T. Khan and F. Wahid, *Int. J. Polym. Sci.*, 2019, **2019**, 1–8.
- 25 A. Sheikhi, J. de Rutte, R. Haghniaz, O. Akouissi, A. Sohrabi, D. Di Carlo and A. Khademhosseini, *MethodsX*, 2019, **6**, 1747–1752.
- 26 J. Laloy, H. Haguët, L. Alpan, D. Raichman, J.-M. Dogné and J.-P. Lellouche, *Nano Converg.*, 2018, **5**, 31.
- 27 K. Ullah, S. A. Khan, A. Mannan, R. Khan, G. Murtaza and M. A. Yameen, *Curr. Pharm. Biotechnol.*, 2020, **21**, 948–954.
- 28 T. Pranati, R. Anitha, S. Rajeshkumar and T. Lakshmi, *Res. J. Pharm. Technol.*, 2019, **12**, 2799–2803.
- 29 L. L. Tshweu, M. A. Shemis, A. Abdelghany, A. Gouda, L. A. Pilcher, N. R. Sibuyi, M. Meyer, A. Dube and M. O. Balogun, *RSC Adv.*, 2020, **10**, 19770–19780.
- 30 S. K. Sahni, *Sustain. Humanosphere*, 2020, **16**, 316–319.
- 31 Y. N. Aung, Y. M. Aung and Z. Z. Yin, *Journal of the Myanmar Academy of Arts and Science*, 2020, **18**, 159.
- 32 V. Gopinath, S. Priyadarshini, M. F. Loke, J. Arunkumar, E. Marsili, D. MubarakAli, P. Velusamy and J. Vadivelu, *Arabian J. Chem.*, 2017, **10**, 1107–1117.
- 33 K. Saritha, A. Rajesh, K. Manjulatha, O. H. Setty and S. Yenugu, *Front. Microbiol.*, 2015, **6**, 577.
- 34 K. Saritha, A. Rajesh, K. Manjulatha, O. H. Setty and S. Yenugu, *Front. Microbiol.*, 2015, **6**, DOI: 10.3389/fmicb.2015.00577.
- 35 M. L. Mangoni, N. Papo, D. Barra, M. Simmaco, A. Bozzi, A. Di Giulio and A. C. Rinaldi, *Biochem. J.*, 2004, **380**, 859–865.
- 36 Z. Zhou, D. Wei, Y. Guan, A. Zheng and J. Zhong, *J. Appl. Microbiol.*, 2010, **108**, 898–907.
- 37 J. Zhao, T. Peng, S. Liang, M. Ma, Z. Zeng, P. Yu, D. Gong and S. Deng, *Food Control*, 2020, **109**, 106953.
- 38 S. M. Navarro Gallón, E. Alpaslan, M. Wang, P. Larese-Casanova, M. E. Londoño, L. Atehortúa, J. J. Pavón and T. J. Webster, *Mater. Sci. Eng., C*, 2019, **99**, 685–695.
- 39 M. Felder, B. S. Trüeb, A. O. Stucki, S. Borcard, J. D. Stucki, B. Schnyder, T. Geiser and O. Guenat, *Front. Bioeng. Biotechnol.*, 2019, **7**, 3.
- 40 K.-S. Lin, A. K. Adhikari, Z.-Y. Tsai, Y.-P. Chen, T.-T. Chien and H.-B. Tsai, *Catal. Today*, 2011, **174**, 88–96.
- 41 S. Sagadevan, Z. Z. Chowdhury and R. F. Rafique, *Mater. Res.*, 2018, **21**, e20160533.
- 42 A. Costa, E. Tortella, M. Morelli and R. Kiminami, *J. Magn. Magn. Mater.*, 2003, **256**, 174–182.
- 43 S. Bhosale, P. Ekambe, S. Bhoraskar and V. Mathe, *Appl. Surf. Sci.*, 2018, **441**, 724–733.
- 44 N. Sattarahmady, M. Heidari, T. Zare, M. Lotfi and H. Heli, *Appl. Magn. Reson.*, 2016, **47**, 925–935.
- 45 I. Khan, K. Saeed and I. Khan, *Arabian J. Chem.*, 2019, **12**, 908–931.
- 46 S. V. K. Rompicharla, P. Kumari, H. Bhatt, B. Ghosh and S. Biswas, *Int. J. Pharm.*, 2019, **557**, 329–341.
- 47 X. Lasheras, M. Insausti, I. Gil de Muro, E. Garaio, F. Plazaola, M. Moros, L. De Matteis, J. s. M. de la Fuente and L. Lezama, *J. Phys. Chem. C*, 2016, **120**, 3492–3500.
- 48 K. M. de la Harpe, P. P. Kondiah, Y. E. Choonara, T. Marimuthu, L. C. du Toit and V. Pillay, *Cells*, 2019, **8**, 1209.



- 49 R. Irshad, K. Tahir, B. Li, A. Ahmad, A. R. Siddiqui and S. Nazir, *J. Photochem. Photobiol., B*, 2017, **170**, 241–246.
- 50 Q. Ran, Y. Xiang, Y. Liu, L. Xiang, F. Li, X. Deng, Y. Xiao, L. Chen, L. Chen and Z. Li, *Sci. Rep.*, 2015, **5**, 16209.
- 51 P. Koli and K. Kapadnis, *Int. J. Chem. Phys. Sci.*, 2014, **4**, 357–360.
- 52 P. C. Lee, C. C. Chu, Y. J. Tsai, Y. C. Chuang and F. D. Lung, *Chem. Biol. Drug Des.*, 2019, **94**(2), 1537–1544.
- 53 N. Babitha, L. S. Priya, S. R. Christy, A. Manikandan, A. Dinesh, M. Durka and S. Arunadevi, *J. Nanosci. Nanotechnol.*, 2019, **19**, 2888–2894.
- 54 V. Sumithra, A. Manikandan, M. Durka, S. K. Jaganathan, A. Dinesh, N. Ramalakshmi and S. A. Antony, *Adv. Sci., Eng. Med.*, 2017, **9**, 483–488.
- 55 K. Elayakumar, A. Manikandan, A. Dinesh, K. Thanrasu, K. Kanmani Raja, R. Thilak Kumar, Y. Slimani, S. K. Jaganathan and A. Baykal, *J. Magn. Magn. Mater.*, 2019, **478**, 140–147.
- 56 S. Kang, M. Pinault, L. D. Pfefferle and M. Elimelech, *Langmuir*, 2007, **23**, 8670–8673.
- 57 R. P. Sharma, S. D. Raut, R. M. Mulani, A. S. Kadam and R. S. Mane, *Int. Nano Lett.*, 2019, **9**, 141–147.
- 58 C. Ehi-Eromosele, J. Olugbuyirozz, O. Taiwo, O. Bamgboye and C. Anjo, *Bull. Chem. Soc. Ethiop.*, 2018, **32**, 451–458.
- 59 D. Thakur, S. Govindaraju, K. Yun and J.-S. Noh, *Nanomaterials*, 2019, **9**, 1431.
- 60 B. G. Manju and P. Raji, *Appl. Phys. A: Mater. Sci. Process.*, 2019, **125**, 313.
- 61 B. G. Manju and P. Raji, *J. Electron. Mater.*, 2019, **48**, 7710–7720.
- 62 B. Ankamwar, *Biomedical Engineering-Technical Applications in Medicine*, 2012, pp. 93–114.
- 63 M. Elsbahy and K. L. Wooley, *Chem. Soc. Rev.*, 2012, **41**, 2545–2561.
- 64 S. Rehman, B. R. Jermy, S. Akhtar, J. F. Borgio, S. Abdul Azeez, V. Ravinayagam, R. Al Jindan, Z. H. Alsalem, A. Buhameid and A. Gani, *Artif. Cells, Nanomed., Biotechnol.*, 2019, **47**, 2072–2082.
- 65 A. Iswarya, B. Vaseeharan, M. Anjugam, B. Ashokkumar, M. Govindarajan, N. S. Alharbi, S. Kadaikunnan, J. M. Khaled and G. Benelli, *Colloids Surf., B*, 2017, **158**, 257–269.
- 66 O. Bondarenko, K. Juganson, A. Ivask, K. Kasemets, M. Mortimer and A. Kahru, *Arch. Toxicol.*, 2013, **87**, 1181–1200.
- 67 A. Sukhanova, S. Bozrova, P. Sokolov, M. Berestovoy, A. Karaulov and I. Nabiev, *Nanoscale Res. Lett.*, 2018, **13**, 44.
- 68 F. Huang, J. Kong, J. Ju, Y. Zhang, Y. Guo, Y. Cheng, H. Qian, Y. Xie and W. Yao, *Sci. Rep.*, 2019, **9**, 490.
- 69 S. A. Anuj, H. P. Gajera, D. G. Hirpara and B. A. Golakiya, *Eur. J. Pharm. Sci.*, 2019, **127**, 208–216.
- 70 M. Arakha, S. Pal, D. Samantarrai, T. K. Panigrahi, B. C. Mallick, K. Pramanik, B. Mallick and S. Jha, *Sci. Rep.*, 2015, **5**, 14813.
- 71 M. Arakha, S. Pal, D. Samantarrai, T. K. Panigrahi, B. C. Mallick, K. Pramanik, B. Mallick and S. Jha, *Sci. Rep.*, 2015, **5**, 14813.
- 72 T. Wang, Z. Jiang, T. An, G. Li, H. Zhao and P. K. Wong, *Environ. Sci. Technol.*, 2018, **52**, 4774–4784.
- 73 K. Muthukumar, D. S. Lakshmi, S. D. Acharya, S. Natarajan, A. Mukherjee and H. C. Bajaj, *Mater. Chem. Phys.*, 2018, **209**, 172–179.
- 74 O. M. Bondarenko, M. Sihtmäe, J. Kuzmičiova, L. Ragelienė, A. Kahru and R. Daugelavičius, *Int. J. Nanomed.*, 2018, **13**, 6779.
- 75 A. Parashar, S. Sikarwar and R. Jain, *J. Dispersion Sci. Technol.*, 2019, 884–894.
- 76 S. J. Kelly, X. Wen, D. P. Arnold and J. S. Andrew, *AIP Adv.*, 2016, **6**, 056105.
- 77 W. R. Li, X. B. Xie, Q. S. Shi, S. S. Duan, Y. S. Ouyang and Y. B. Chen, *BioMetals*, 2011, **24**, 135–141.
- 78 J. Yang, J. Y. Lee and H. P. Too, *Anal. Chim. Acta*, 2007, **588**, 34–41.
- 79 L. Salvioni, E. Galbiati, V. Collico, G. Alessio, S. Avvakumova, F. Corsi, P. Tortora, D. Prospero and M. Colombo, *Int. J. Nanomed.*, 2017, **12**, 2517.
- 80 R. P. Sharma, S. D. Raut, R. M. Mulani, A. S. Kadam and R. S. Mane, *Int. Nano Lett.*, 2019, **9**, 141–147.
- 81 Y. Gao, M. Arokia Vijaya Anand, V. Ramachandran, V. Karthikkumar, V. Shalini, S. Vijayalakshmi and D. Ernest, *J. Cluster Sci.*, 2019, **30**, 937–946.
- 82 K. Steffy, G. Shanthi, A. S. Maroky and S. Selvakumar, *J. Infect. Public Health*, 2018, **11**, 463–471.
- 83 L. Zhang, L. Wu, Y. Mi and Y. Si, *Bull. Environ. Contam. Toxicol.*, 2019, 1–6.
- 84 X. Lin, J. Li, S. Ma, G. Liu, K. Yang, M. Tong and D. Lin, *PLoS One*, 2014, **9**, e110247.
- 85 M. M. Naik, H. S. B. Naik, N. Kottam, M. Vinuth, G. Nagaraju and M. C. Prabhakara, *J. Sol-Gel Sci. Technol.*, 2019, **91**, 578–595.
- 86 S. Dong, J. Xu, T. Jia, M. Xu, C. Zhong, G. Yang, J. Li, D. Yang, F. He and S. Gai, *Chem. Sci.*, 2019, **10**, 4259–4271.
- 87 V. P. Giri, S. Pandey, M. Kumari, S. K. Paswan, A. Tripathi, M. Srivastava, C. V. Rao, R. Katiyar, C. S. Nautiyal and A. Mishra, *FEMS Microbiol. Lett.*, 2019, **366**(16), fnz201.
- 88 M. Moniri, A. B. Moghaddam, S. Azizi, R. A. Rahim, S. W. Zuhainis, M. Navaderi and R. Mohamad, *Int. J. Nanomed.*, 2018, **13**, 5097.

